Seikagaku: Seikagaku and Ono Reach a Basic Agreement Related to Co-development and Marketing Collaboration on Gel-One in Japan
Seikagaku: Notice of conclusion of a basic agreement on joint development and sales partnership for osteoarthritis treatment “Gel-One”
Seikagaku: Notice regarding organizational changes and changes in officers, etc.
Seikagaku: Notice regarding revisions to the full-year consolidated earnings forecast for the fiscal year ending March 31, 2025
Seikagaku: Change reports (stock certificates subject to special cases, etc.)
Seikagaku: Receipt of an examination completion report notification relating to the US approval application for SI-6603 (generic name: chondriase)
Seikagaku: Notice regarding the commencement of phase III clinical trials of the osteoarthritis remedy “Gel-One” in Japan
Seikagaku: Summary of Financial Results for the 3rd Quarter of the Fiscal Year Ending March 31, 2025 [Japanese GAAP] (Consolidated)
Seikagaku: Notice regarding changes in officers, etc.
Seikagaku: Confirmatory letter.
Seikagaku: Half Year Report - Term 79 (2024/04/01 - 2025/03/31)
Seikagaku: Summary of financial results for the 2nd quarter (interim period) of the fiscal year ending 2025/3 [Japanese GAAP] (consolidated)
Seikagaku: Change Report
Seikagaku: Notice regarding approval of the endoscopic submucosal injection material “MuCoUP” in China and the conclusion of a sales agency agreement with Tozai Trading Co., Ltd.
Seikagaku: Notice regarding organizational changes and personnel changes
Seikagaku: Change report (exemption share certificates, etc.)
Seikagaku: Change Report
Seikagaku: March 2025 first quarter financial statement announcement [Japan Standard] (consolidated)
Seikagaku: Announcements of individual stocks related to personnel changes.
Change report (exemption share certificates, etc.)